QuantumPharm, Inc. (2228) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 126.65M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.66
• Revenue Growth: 50.10%
• EPS Growth: -212.76%
• Country: HK
• Employees: 809
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -1.93
• Shares Outstanding: 4,019,811,800
• 10 Day Avg. Volume: 116,650,222
• 30 Day Avg. Volume: 126,654,427
• PEG Ratio: 0.04
• Price to Book (P/B): -0.34
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.87
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$7.57
• Price Target Upside: 30.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 49 Neutral
• Price Target: HK$5.50 ▼(-5.34%Downside)

QuantumPharm, Inc. faces significant challenges despite strong revenue growth, primarily due to persistent net losses and negative cash flows. Technical indicators suggest short-term bullishness, but the poor valuation metrics, highlighted by a negative P/E ratio, weigh heavily on the overall score.

Positive Factors

Financial Strength

The company further strengthened its financial position by completing two fundraising placements raising HK$3.2bn to enhance its cash reserves and fund future growth initiatives.

Partnerships

XtalPi collaborates with leading global and domestic pharma companies, enhancing its strategic position in drug discovery.

Revenue Growth

XtalPi leverages its proprietary AI-powered R&D platform to deliver stable and accelerating revenue growth across two core business areas: drug discovery and intelligent robotics.

Negative Factors

Commercialization Risks

Risks relating to R&D progress of drug candidates in partnerships, sustainability of commercialization, and shareholder sell-off.

R&D Risks

Risks include potential delays in partnered R&D pipelines, uncertainty in commercialization sustainability, and possible sell-off following lock-up expiry.

QuantumPharm, Inc. Business Overview & Revenue Model

Company Description

QuantumPharm, Inc. (2228) is a leading biotechnology company specializing in the development and commercialization of quantum-enhanced pharmaceuticals. The company operates within the healthcare and technology sectors, focusing on leveraging quantum computing technologies to accelerate drug discovery and development. QuantumPharm's core products include a range of proprietary medications and therapeutic solutions aimed at treating complex diseases more efficiently than traditional methods.

How the Company Makes Money

QuantumPharm, Inc. generates revenue through the commercialization of its quantum-enhanced pharmaceuticals. The company's primary revenue streams include the sale of proprietary medications to healthcare providers, licensing agreements with other pharmaceutical companies, and partnerships with research institutions for joint drug development projects. Additionally, QuantumPharm benefits from government grants and subsidies aimed at fostering innovation in biotechnology. The company's strategic alliances with technology firms also contribute to its earnings by enabling access to cutting-edge quantum computing resources, which enhance its drug discovery processes and reduce development costs.

QuantumPharm, Inc. Financial Statement Overview

Summary

QuantumPharm, Inc. shows strong revenue growth, but ongoing losses and negative cash flows are concerning. Improvements in debt and equity provide some stability, but profitability and cash flow issues remain critical challenges.

Income Statement

QuantumPharm, Inc. has shown significant revenue growth from 2019 to 2024, yet the company struggles with profitability. Gross Profit Margin improved to 46.31% in 2024 from 27.66% in 2023, but the company continues to incur substantial net losses, with a Net Profit Margin of -569.33% in 2024. The negative EBIT and EBITDA margins highlight ongoing operational challenges.

Balance Sheet

The company has made notable improvements in its balance sheet, reducing total debt significantly from 2023 to 2024. The Debt-to-Equity Ratio has improved due to a positive equity position in 2024. However, the Equity Ratio remains a concern, reflecting potential financial instability.

Cash Flow

Operating Cash Flow has improved slightly, yet remains negative, impacting the company's ability to generate positive Free Cash Flow. Despite the improvement in financing activities, the Free Cash Flow to Net Income Ratio remains unfavorable, indicating ongoing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2019
Income Statement
Total Revenue	102.63M	266.43M	174.42M	133.35M	62.80M	0.00
Gross Profit	47.15M	123.43M	48.24M	66.09M	32.78M	0.00
EBITDA	-388.72M	-631.38M	-1.78B	-390.37M	-2.11B	-9.84M
Net Income	-1.24B	-1.52B	-1.91B	-1.44B	-2.14B	-36.03M
Balance Sheet
Total Assets	4.46B	4.35B	4.01B	4.32B	4.38B	8.44M
Cash, Cash Equivalents and Short-Term Investments	3.39B	3.10B	2.83B	3.47B	3.83B	8.44M
Total Debt	163.57M	148.76M	11.04B	9.45B	7.83B	159.05M
Total Liabilities	321.07M	362.43M	11.25B	9.63B	7.99B	219.45M
Stockholders Equity	4.12B	3.96B	-7.27B	-5.33B	-3.61B	-211.01M
Cash Flow
Free Cash Flow	-331.31M	-536.79M	-698.20M	-627.83M	-417.42M	655.00K
Operating Cash Flow	-299.29M	-478.68M	-567.56M	-429.10M	-253.75M	655.00K
Investing Cash Flow	48.65M	74.09M	735.58M	-2.76B	-70.47M	33.00K
Financing Cash Flow	828.06M	840.00M	-25.89M	57.99M	2.48B	0.00

QuantumPharm, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.81
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2228, the sentiment is Positive. The current price of 5.81 is above the 20-day moving average (MA) of 5.62, above the 50-day MA of 5.07, and below the 200-day MA of 6.58, indicating a neutral trend. The MACD of 0.20 indicates Positive momentum. The RSI at 56.27 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2228.

QuantumPharm, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2268	73 Outperform	HK$50.04B	42.99	17.75%	―	―	―
Sector *	57 Neutral	HK$22.27B	11.05	-15.60%	15.93%	10.12%	-85.27%
2509	57 Neutral		―		―	―	―
2502	53 Neutral		7.33	-1.60%	5.42%	30.77%	-128.09%
2228	49 Neutral		―		―	50.10%	-212.76%
2498	41 Neutral	HK$15.40B	―	-12.70%	―	―	―
2511	36 Underperform	HK$1.36B	―	-67.57%	―	―	54.79%

QuantumPharm, Inc. Corporate Events

XtalPi Partners with DoveTree for AI-Driven Drug Discovery

XtalPi Holdings Limited has entered into a term sheet with DoveTree LLC to collaborate on drug discovery using its AI and robotics platform. This partnership will focus on developing small molecule and antibody drug candidates for tumors, autoimmune, and neurological diseases, potentially leading to significant financial gains and global commercialization rights for DoveTree.

The most recent analyst rating on (HK:2228) stock is a Buy with a HK$7.57 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.

XtalPi Co-Founders Extend Lock-Up, Signaling Confidence

XtalPi Holdings Limited, a company incorporated in the Cayman Islands, has announced that its co-founders have voluntarily extended their lock-up undertakings for another year, demonstrating their confidence in the company’s long-term value and future prospects. This extension involves a total of 591,488,405 shares, representing 14.71% of the issued share capital, and is seen as a positive signal for stakeholders, potentially stabilizing the company’s stock and reinforcing its market position.

The most recent analyst rating on (HK:2228) stock is a Buy with a HK$7.57 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.

XtalPi Holdings Acquires 90% Stake in Target Company for RMB250 Million

XtalPi Holdings Limited, a company incorporated in the Cayman Islands, has announced a significant acquisition involving a 90% equity interest in a target company for RMB250 million, to be fully settled in cash. This transaction is considered a discloseable transaction under the Listing Rules, as it exceeds the 5% threshold but is below 25%, thus requiring reporting and announcement. The acquisition will result in the target company becoming an indirect non-wholly owned subsidiary of XtalPi, potentially enhancing its market position and operational capabilities.

XtalPi Holdings AGM Resolutions Passed with Overwhelming Support

XtalPi Holdings Limited, a company incorporated in the Cayman Islands, held its Annual General Meeting on April 29, 2025, where all proposed resolutions were passed with significant majority support. Key resolutions included the re-election of directors, re-appointment of auditors, and granting mandates for share allotment and repurchase, reflecting strong shareholder confidence and strategic alignment for future growth.

XtalPi Holdings Limited Announces 2025 AGM and Key Resolutions

XtalPi Holdings Limited has announced its upcoming Annual General Meeting (AGM) scheduled for April 29, 2025, in Shenzhen, China. The meeting will address several key resolutions, including the re-election of directors, the re-appointment of PricewaterhouseCoopers as the company’s auditor, and a proposal to authorize the board to issue additional shares. These resolutions are aimed at strengthening the company’s governance and operational capabilities, potentially impacting its market position and stakeholder interests.

XtalPi Achieves Commercial Company Status on Hong Kong Stock Exchange

XtalPi Holdings Limited, a company incorporated in the Cayman Islands, has announced that it has achieved the revenue threshold required to be classified as a Commercial Company under the Hong Kong Stock Exchange’s Listing Rules. As a result, the Stock Exchange has approved the removal of its designation as a Pre-Commercial Company, marking a significant milestone in its business development. This change in status reflects the company’s growth and positions it more favorably within the industry, potentially impacting its stakeholders positively.